MA27626A1 - Nouveaux derives de 2-pyridinecarboxamide - Google Patents

Nouveaux derives de 2-pyridinecarboxamide

Info

Publication number
MA27626A1
MA27626A1 MA28455A MA28455A MA27626A1 MA 27626 A1 MA27626 A1 MA 27626A1 MA 28455 A MA28455 A MA 28455A MA 28455 A MA28455 A MA 28455A MA 27626 A1 MA27626 A1 MA 27626A1
Authority
MA
Morocco
Prior art keywords
atom
formula
elements
group
oxygen
Prior art date
Application number
MA28455A
Other languages
English (en)
Inventor
Teruyuki Nishimura
Jun-Ichi Eiki
Morihiro Mitsuya
Makoto Bamba
Fumiko Sakai
Hitomi Watanabe
Yasuhiro Sasaki
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of MA27626A1 publication Critical patent/MA27626A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un composé qui a un effet activateur de la glucokinase et est utile comme agent thérapeutique contre le diabète sucré, étant représenté par une formule (I): [dans laquelle X1 représente un atome d'azote, atome de soufre, atome d'oxygène ou ceux semblables; R1 représente un groupement aryle de 6 à 10 éléments, groupement hétéroaryle de 5 à 7 éléments ou ceux semblables; D représente un atome d'oxygène ou atome de soufre; R2 et R3 sont les mêmes ou différents, chacun représentant un atome d'hydrogène, groupement alkyle inférieur ou ceux semblables; une formule (II) représente un groupement hétéroaryle facultativement substitué de 5 à 7 éléments ou ceux semblables; une formule (III) représente un groupement monocyclique ou bicyclique] ou un sel pharmaceutiquement acceptable de celui-ci.
MA28455A 2003-02-13 2005-08-24 Nouveaux derives de 2-pyridinecarboxamide MA27626A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003034987 2003-02-13
JP2003342860 2003-10-01
JP2004014799 2004-01-22

Publications (1)

Publication Number Publication Date
MA27626A1 true MA27626A1 (fr) 2005-11-01

Family

ID=32995582

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28455A MA27626A1 (fr) 2003-02-13 2005-08-24 Nouveaux derives de 2-pyridinecarboxamide

Country Status (20)

Country Link
US (3) US7629362B2 (fr)
EP (1) EP1598349B1 (fr)
JP (1) JP4400563B2 (fr)
KR (1) KR20050101208A (fr)
AR (1) AR045414A1 (fr)
AT (1) ATE517887T1 (fr)
AU (2) AU2004220234C1 (fr)
BR (1) BRPI0407283A (fr)
CA (1) CA2515841C (fr)
EC (1) ECSP056016A (fr)
IL (1) IL169905A0 (fr)
MA (1) MA27626A1 (fr)
MX (1) MXPA05008619A (fr)
NO (1) NO20054224L (fr)
NZ (1) NZ540791A (fr)
PE (1) PE20050194A1 (fr)
TW (1) TWI336329B (fr)
UA (1) UA82867C2 (fr)
WO (1) WO2004081001A1 (fr)
ZA (1) ZA200504852B (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7312044B2 (en) 2003-03-07 2007-12-25 The Trustees Of Columbia University In The City Of New York Type 1 ryanodine receptor-based methods
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
PL375021A1 (en) 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
BRPI0407283A (pt) 2003-02-13 2006-01-31 Banyu Pharma Co Ltd Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
US7728025B2 (en) * 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
EP1715867A4 (fr) * 2004-02-12 2009-04-15 Merck & Co Inc Amides bipyridyles en tant que modulateurs du r cepteur-5 metabotropique du glutamate
US7781451B2 (en) 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
PT1735322E (pt) 2004-04-02 2012-01-12 Novartis Ag Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2
WO2006038741A1 (fr) 2004-10-08 2006-04-13 Banyu Pharmaceutical Co., Ltd Méthode de synthèse d’un composé de type thioéther
BRPI0517232A (pt) 2004-11-02 2008-10-07 Banyu Pharma Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade
ZA200708144B (en) * 2005-02-25 2008-11-26 Takeda Pharmaceutical Pyridyl acetic acid compounds
ES2476840T3 (es) 2005-03-04 2014-07-15 F. Hoffmann-La Roche Ag Derivados de piridina-2-carboxamida como antagonistas de MGLUR5
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
ATE466003T1 (de) 2005-08-05 2010-05-15 Bristol Myers Squibb Co Herstellung von 2-aminothiazol-5- carbonsäurederivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
NZ566877A (en) 2005-09-29 2010-05-28 Sanofi Aventis Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
JP4990783B2 (ja) * 2005-09-30 2012-08-01 Ｍｓｄ株式会社 ２−ヘテロアリール置換インドール誘導体
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
BRPI0616865A2 (pt) 2005-10-05 2011-07-05 Hoffmann La Roche compostos derivados de naftiridina, processo para preparação dos mesmos, medicamentos e uso dos mesmos
EP1948652B1 (fr) * 2005-11-01 2011-08-24 Array Biopharma, Inc. Activateurs de glucokinase
EP2001875A2 (fr) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Activateurs de la glucokinase
RS53981B1 (sr) 2006-03-24 2015-10-30 Array Biopharma Inc. Analozi 2-aminopiridina kao aktivatori glukokinaze
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2049518B1 (fr) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Derives de l'indazole et de l'isoindazole comme agents de l'activation de glucokinase
JP2009544648A (ja) 2006-07-24 2009-12-17 エフ．ホフマン−ラ ロシュ アーゲー グルコキナーゼ活性化剤としてのピラゾール類
AR063028A1 (es) 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
EP2086973B1 (fr) * 2006-10-11 2012-01-25 Amgen Inc., Composés d'imidazo- et de triazolo-pyridine et leurs procédés d'utilisation
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
WO2008084872A1 (fr) 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation Dérivé d'hydrazone
US8431713B2 (en) 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
WO2008116107A2 (fr) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Activateurs de glucokinase
JP5450108B2 (ja) * 2007-03-23 2014-03-26 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤としての２−アミノピリジン類似体
JP2010138073A (ja) * 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
WO2008156174A1 (fr) 2007-06-21 2008-12-24 Taisho Pharmaceutical Co., Ltd. Composé de pyrazinamide
EP2020232A1 (fr) * 2007-08-03 2009-02-04 Zeltia, S.A. Dérives de N-(1-thiazolyl)-amide pour traiter l'obésité, le diabète et des maladies cardiovasculaires
EA019104B1 (ru) * 2007-09-21 2014-01-30 Эррей Биофарма Инк. Активаторы глюкокиназы
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009061271A1 (fr) 2007-11-06 2009-05-14 Astrazeneca Ab Certains dérivés de 2-pyrazinone et leur utilisation comme inhibiteurs d'élastase des neutrophiles
AU2008321959B2 (en) 2007-11-12 2014-02-13 Msd K.K. Heteroaryloxy quinazoline derivative
JPWO2009081782A1 (ja) 2007-12-25 2011-05-06 萬有製薬株式会社 Ｎ−ピラゾール−２−ピリジンカルボキサミド誘導体
WO2009083553A1 (fr) * 2007-12-31 2009-07-09 Rheoscience A/S Composés azines en tant qu'activateurs de glucokinase
EP2245025A1 (fr) * 2008-02-27 2010-11-03 Merck Patent GmbH Dérivés d'hétéroaryl-carboxamides utilisés pour le traitement du diabète
JP5455380B2 (ja) * 2008-03-12 2014-03-26 公益財団法人相模中央化学研究所 新規なチアゾール誘導体、及びその製造方法
WO2009113637A1 (fr) * 2008-03-12 2009-09-17 東ソー株式会社 Nouveau dérivé de thiazole, matrice ayant un dérivé de thiazole immobilisé sur celle-ci, procédé de fabrication du dérivé de thiazole et procédé de fabrication de la matrice
JP5498025B2 (ja) * 2008-03-13 2014-05-21 公益財団法人相模中央化学研究所 新規なチアゾール誘導体固定化マトリックス、及びその製造方法
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
JP2012500181A (ja) 2008-08-15 2012-01-05 Ｍｓｄ株式会社 アセチルピロリジニルインドール誘導体
CA2734981A1 (fr) * 2008-08-29 2010-03-04 Banyu Pharmaceutical Co., Ltd. Derive d'oxotetrahydrofurann-2-yl-benzimidazole
GEP20135793B (en) 2008-09-11 2013-03-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
WO2010103437A1 (fr) 2009-03-11 2010-09-16 Pfizer Inc. Dérivés de benzofuranyle utilisés comme inhibiteurs de la glucokinase
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
US20110021570A1 (en) * 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
CA2768577A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composes d?oxazepine benzofusionnes en tant qu?inhibiteurs de la coenzyme-stearoyle a delta-9 desaturase
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
CN102884047B (zh) 2009-12-04 2015-11-25 日产化学工业株式会社 2-吡啶酮化合物
US8222416B2 (en) * 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
CA2870488A1 (fr) 2012-04-16 2013-10-24 Kaneq Pharma Inc. Derives de phosphonates aromatiques fusionnes utilises comme precurseurs d'inhibiteurs de ptp-1b
US9527838B2 (en) 2012-12-17 2016-12-27 Merck Sharp & Dohme Corp. 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment
EA201692155A1 (ru) 2014-05-13 2017-04-28 Мемориал Слоун-Кеттеринг Кэнсэ Сентр МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
US20240067657A1 (en) * 2020-12-29 2024-02-29 Merck Sharp & Dohme Llc Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses
IL280384B (en) * 2021-01-25 2022-09-01 Ag Plenus Ltd Herbicidal compounds and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS56115784A (en) 1980-02-15 1981-09-11 Tanabe Seiyaku Co Ltd Novel pyridinecarboxamide derivative and its preparation
JPS5795984A (en) 1980-12-05 1982-06-15 Tanabe Seiyaku Co Ltd Pyridinecarboxamide derivative and its preparation
JPS58121215A (ja) 1982-01-14 1983-07-19 Tanabe Seiyaku Co Ltd 抗アレルギ−剤
CH680582A5 (fr) 1991-04-23 1992-09-30 Supermatic Kunststoff Ag
GB2277930A (en) 1993-05-11 1994-11-16 Shell Int Research Herbicidal picolinamide derivatives
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
JP2002047278A (ja) 2000-08-02 2002-02-12 Fuji Photo Film Co Ltd チオエーテル化合物の製造方法
JP4723059B2 (ja) 2000-08-03 2011-07-13 帝人化成株式会社 難燃性熱可塑性樹脂組成物
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE519859C2 (sv) 2001-08-17 2003-04-15 Novacast Ab Anordning för behandling av järnlegeringar i ett kärl
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
AU2002952839A0 (en) 2002-11-21 2002-12-05 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
BRPI0407283A (pt) 2003-02-13 2006-01-31 Banyu Pharma Co Ltd Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
WO2004076420A1 (fr) * 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. Derives d'heteroarylcarbamoylbenzene
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
EP2048137A1 (fr) 2004-02-18 2009-04-15 AstraZeneca AB Dérivés de la benzamide et leur utilisation comme activateurs de la glucokinase.
JP2007523905A (ja) 2004-02-18 2007-08-23 アストラゼネカ アクチボラグ 化合物
WO2006038741A1 (fr) 2004-10-08 2006-04-13 Banyu Pharmaceutical Co., Ltd Méthode de synthèse d’un composé de type thioéther
AR063028A1 (es) * 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
AR068540A1 (es) 2007-09-28 2009-11-18 Merck & Co Inc Metodos de produccion de un derivado de pirazol-3-il-benzamida.

Also Published As

Publication number Publication date
US8765789B2 (en) 2014-07-01
MXPA05008619A (es) 2005-11-04
KR20050101208A (ko) 2005-10-20
IL169905A0 (en) 2007-07-04
AU2004220234B2 (en) 2009-11-26
US20060258701A1 (en) 2006-11-16
UA82867C2 (en) 2008-05-26
EP1598349B1 (fr) 2011-07-27
NO20054224D0 (no) 2005-09-12
TW200510381A (en) 2005-03-16
ATE517887T1 (de) 2011-08-15
ECSP056016A (es) 2006-01-27
NZ540791A (en) 2009-09-25
AR045414A1 (es) 2005-10-26
US7629362B2 (en) 2009-12-08
HK1088602A1 (zh) 2006-11-10
NO20054224L (no) 2005-11-10
CA2515841C (fr) 2010-06-01
US20100041660A1 (en) 2010-02-18
AU2004220234A1 (en) 2004-09-23
TWI336329B (en) 2011-01-21
US8344003B2 (en) 2013-01-01
PE20050194A1 (es) 2005-04-23
JPWO2004081001A1 (ja) 2006-06-08
AU2010200004B2 (en) 2012-07-19
US20130085156A1 (en) 2013-04-04
EP1598349A1 (fr) 2005-11-23
EP1598349A4 (fr) 2008-12-31
ZA200504852B (en) 2006-05-31
AU2004220234C1 (en) 2013-01-17
AU2010200004A1 (en) 2010-01-28
WO2004081001A1 (fr) 2004-09-23
BRPI0407283A (pt) 2006-01-31
CA2515841A1 (fr) 2004-09-23
JP4400563B2 (ja) 2010-01-20

Similar Documents

Publication Publication Date Title
BRPI0413232A (pt) novos compostos tendo atividade inibitória contra os trasnportadores dependentes de sódio
DK0612321T3 (da) Pyridopyridazinon- og pyridazinthionforbindelser med PDE IV inhiberende aktivitet
DE60236851D1 (en) Pyrimidinmatrixmetalloproteinaseinhibitoren
MA29773B1 (fr) Derives de 1-h-pyrrole substitues par un groupe 1-heterocyclysulfonyle, 2-aminomethyle, 5-(hetero) aryle en tant qu'inhibiteurs des secretions acides
MA28024A1 (fr) Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2
HUP0004259A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
MA29323B1 (fr) Composes de l'acide pyridylacetique
MA30813B1 (fr) Derives de 2-pyridinecarboxamide ayant un effet d'activation sur la gk.
EA200300763A1 (ru) Пиридиновые ингибиторы матриксных металлопротеиназ
EP1426366A4 (fr) Derive thiazolidine et son utilisation medicamenteuse
EP1259487B8 (fr) Derives de 2-amino-nicotinamide et leur utilisation comme inhibiteurs de tyrosine kinase du recepteur vegf
DE69514367D1 (de) Substituierte amidderivate
LU91210I2 (fr) Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
HUP0004529A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
MA30029B1 (fr) Derives spiro aza-substitue
MA30524B1 (fr) Agent de lutte antiparasite contenant un nouveau derive de pyridyl-methanamine ou un sel de celui-ci
MA29250B1 (fr) Cyclohexylamides servant d'antagonistes des recepteurs de dopamine d3, d2 et de 5ht1a
EA200601235A1 (ru) Производные тиазола
DE60103136D1 (de) Imidazol derivate als raf kinase inhibitoren
EA200401615A1 (ru) ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
NZ330973A (en) Azolobenzazepine derivatives as neurologically active agents
WO2004004730A3 (fr) Composes pharmaceutiques
DE69731940D1 (de) Uracilderivate enthaltende krebsmetastasen inhibitoren
CA2398772A1 (fr) Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2 4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant